Contineum Therapeutics, Inc. PIPE-791 is being developed for the treatment of neuroinflammatory disorders like idiopathic pulmonary fibrosis and Progressive Multiple Sclerosis. The global idiopathic ...
Pertuzumab-dpzb is now considered an interchangeable biosimilar to pertuzumab as part of treatment combinations in multiple ...
The "LAG-3 Antagonist – Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com’s offering. This "LAG-3 Antagonist – Pipeline Insight, 2021," report provides comprehensive ...
Growth hormone receptor (GHR) signaling in bladder cancer is associated with advanced tumor stages and poor survival outcomes. High GHR expression in tumors up-regulates genes involved in drug ...
ST316 interfered with β-catenin immune-exclusion allowing for stronger cytotoxic T-cell activity. The Food and Drug Administration (FDA) has granted Orphan Drug designation to ST316 for the treatment ...
Focusing on pharmacokinetic and pharmacodynamic mechanisms, Dr Erin C Berthold discusses the interactions between botanical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback